Brigham Young University revealed on Thursday that its FDA listed alcohol-free Disinfect & Shield hand sanitizer containing benzalkonium chloride are just as effective against the COVID-19 virus as alcohol-based products based on a new research based study.
The new study was reportedly published in The Journal of Hospital Infection.
According to the university , the Disinfect & Shield Hand Sanitizer is available as a moisture-infused foam or spray that leaves an invisible, breathable barrier on the skin. It not only destroys 99.99% of bacteria but is also eco-friendly, making it ultra-safe for use around pets and plants while protecting the treated area for up to a full eight hours. The product is effective against numerous viruses, bacteria, moulds, and fungi enveloped and non- enveloped, including strains of SARS, MRSA and Staph infection.
Disinfect & Shield is a fast-acting nanotechnology that destroys viruses and bacteria and prevents them from attaching to skin, surfaces, and clothes. The colourless, odourless, positively charged polymer bonds to the treated surface creating a layer of electrically charged swords. They protect the surface from biofilm growth by puncturing the cell membrane. It is alcohol-free and eliminates the harsh fumes and cracked, dry skin that accompanies alcohol-based sanitizers and its safe for use on PPE like gloves, concluded the university.
AstraZeneca's Fasenra misses primary endpoint in Phase III COPD trial
Hemogenyx reports positive safety and early efficacy data from third patient in CAR-T trial
Sanofi reports positive phase 2a results for brivekimig in hidradenitis suppurativa
GSK commits USD30bn to US R&D and manufacturing expansion
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial